The Pharmacological Basis of SGLT2 Inhibitor-Mediated Kidney Protection: From Proximal Tubular Mechanisms to Clinical Outcomes
Drugs · 19.11.2026
DOI: 10.1007/s40265-026-02416-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 19.11.2026. Verfasst von Hussein Zaitoon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Division, University of Texas Health Science Center at San Antonio and Texas Diabetes Institute, 7703 Floyd Curl Drive, San Antonio, TX, 782…. Die Arbeit nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Diabetes Division, University of Texas Health Science Center at San Antonio and Texas Diabetes Institute, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.
- Diabetes Division, University of Texas Health Science Center at San Antonio and Texas Diabetes Institute, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA. defronzo@uthscsa.edu.
Zitieren
APA
Zaitoon, H., Abdul-Ghani, M., & DeFronzo, R. A. (2026). The Pharmacological Basis of SGLT2 Inhibitor-Mediated Kidney Protection: From Proximal Tubular Mechanisms to Clinical Outcomes. Drugs. https://doi.org/10.1007/s40265-026-02416-9
Vancouver
Zaitoon H, Abdul-Ghani M, DeFronzo RA. The Pharmacological Basis of SGLT2 Inhibitor-Mediated Kidney Protection: From Proximal Tubular Mechanisms to Clinical Outcomes. Drugs. 2026. doi:10.1007/s40265-026-02416-9
BibTeX
@article{Zaitoon2026,
author = {Zaitoon, Hussein and Abdul-Ghani, Muhammad and DeFronzo, Ralph A},
title = {The Pharmacological Basis of SGLT2 Inhibitor-Mediated Kidney Protection: From Proximal Tubular Mechanisms to Clinical Outcomes},
journal = {Drugs},
year = {2026},
doi = {10.1007/s40265-026-02416-9}
}
EUVIMED